Preclinical studies have shown that the combination of cyclin-dependent kinase 4/6 (CDK4/6) and MEK inhibitors can improve the responsiveness of MPNST to anti-PD-L1 immune checkpoint blockade (ICB) [28]. This evidence concerns the gene MAP2K7 and malignant peripheral nerve sheath tumor.